Hospital acquired urinary tract infections are caused by patients urethral catheters or invasive manipulation in the urogenital tract, which allows microbes to enter into the bladder and encourages proliferation by providing a sustainable environment. Hospital acquired UTIs are accountable for over 50% of infections. An array of tests can uncover type of infection and pathogen associated with the infection to efficiently treat the infected area.
Increase in prevalence of hospital acquired UTIs and technological advancement in testing devices drive the market. Moreover, favorable reimbursement scenario and focused disease management boost the market growth. However, strict regulatory policies and introduction of new testing devices into the market restrict the growth. Surge in preference over substitute products such as anti-infection catheters impedes the market growth.
The global hospital acquired urinary tract infection market is segmented on the basis of product, application, technology, disease, end user, and geography. On the basis of product, the market is divided into microbial testing instruments, reagents and consumables, infection prevention, and surveillance software. The microbial testing instruments are further divided into automated microbial identification systems, polymerase chain reaction (PCR) instruments, mass spectrometers, microarrays, polystainers, flow cytometers, and others. By application, the market is classified into disease testing, drug-resistance testing. On the basis of technology, the market is divided into phenotypic methods (phage-based assays, colorimetric methods, and nitrate reductase assay) and genotypic methods (DNA sequencing, solid-phase hybridization techniques, polymerase chain reaction techniques, microarrays). By diseases, the market is categorized into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections (UTI), and others. By end user, the market is segmented into hospitals and intensive care units (ICUs), ambulatory surgical and diagnostic centers, nursing homes and maternity centers, and others. By geography, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Advanced Sterilization Products (Division Ethicon Us, LLC), Becton, Dickinson and Company, Steris Corporation, Getinge Group, Kimberly-Clark Corporation, Cantel Medical, Biomerieux SA, Belimed AG, 3M Company, Sterigenics International LLC., Synergy Health, and PLC are provided in this report.
Key Benefits
- The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
- Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework
- It offers a quantitative analysis to enable the stakeholders to capitalize on the prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
Hospital Acquired Urinary Tract Infection Market, by Product Report Highlights
| Aspects | Details |
 By Product |
|
 By Application |
|
 By Technology |
|
 By Disease |
|
 By End User |
|
 By Region |
|
 Key Market Players | Steris Corporation, Sterigenics International LLC., Becton, Dickinson and Company, Advanced Sterilization Products (Division Ethicon Us, LLC), Biomerieux SA, Cantel Medica, Getinge Group,, Kimberly-Clark Corporation,, 3M Company, Belimed AG |
Loading Table Of Content...
